MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.

about

MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.

Item

http://www.wikidata.org/entity/Q55360749

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

MGMT promoter methylation and ...... cell neuroendocrine carcinoma.

@en

MGMT promoter methylation and ...... cell neuroendocrine carcinoma.

@nl

type

Item

label

MGMT promoter methylation and ...... cell neuroendocrine carcinoma.

@en

MGMT promoter methylation and ...... cell neuroendocrine carcinoma.

@nl

prefLabel

MGMT promoter methylation and ...... cell neuroendocrine carcinoma.

@en

MGMT promoter methylation and ...... cell neuroendocrine carcinoma.

@nl

P1476

MGMT promoter methylation and ...... -cell neuroendocrine carcinoma

@en

P2093

Gu Zhang

http://www.w3.org/2001/XMLSchema#string

Lei Lei

http://www.w3.org/2001/XMLSchema#string

Qiaoyuan Cheng

http://www.w3.org/2001/XMLSchema#string

Zhiming Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.

Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma.

O6-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer.

Advances in neuroendocrine lung tumors.

Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases.

Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent.

Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.

P2888

s12957-018-1413-7

P304

110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12957-018-1413-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hongyang Lu

P577

2018-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104900721

http://www.w3.org/2001/XMLSchema#string

P698

29914531

http://www.w3.org/2001/XMLSchema#string

P932

6007073

http://www.w3.org/2001/XMLSchema#string